Natco Pharma vs Glenmark Life Sciences: Share Price, Comparison and Key Differences
- August 12, 2026
- Posted by: Kunal Singla
- Category: News
Natco Pharma MCap Rs 16,427 Cr, PE 11.58x (very cheap!), ROE 15.38%, D/E 0.08. Glenmark Life Sciences MCap Rs 16,308 Cr, PE 27.04x, ROE 16.94%, D/E 0.02.
Natco Pharma vs Glenmark Life Sciences is a comparison pharma investors look up when evaluating two listed Indian companies with different pharma strategies. Natco Pharma, a Hyderabad-based company, focuses on complex generic formulations – particularly oncology, hepatitis C and cardiovascular drugs – for export to regulated markets (USA, Europe) and the domestic market. Glenmark Life Sciences, a Mumbai-based company and subsidiary of Glenmark Pharmaceuticals, is a contract research and manufacturing services (CRAMS) company providing APIs (active pharmaceutical ingredients) and complex chemistry services for branded and generic pharma companies globally. Natco Pharma vs Glenmark Life Sciences cover contrasting pharma models.
This Natco Pharma vs Glenmark Life Sciences article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.
Reach and Market Position
In this Natco Pharma vs Glenmark Life Sciences comparison, Natco Pharma sells complex generic medicines in the US market and other countries through its own and partner filings, and domestic branded formulations. Market capitalisation is Rs 16,427 Cr.
Click Here – Get Free Investment Predictions
Glenmark Life Sciences manufactures APIs for global pharma companies through its sites in India (Ankleshwar, Dahej) and provides CDMO (contract development and manufacturing) services. Market capitalisation is Rs 16,308 Cr.
Key Products and Business Mix
For the Natco Pharma vs Glenmark Life Sciences product breakdown, Natco Pharma: Natco earns from complex generic oncology, anti-hepatitis C and cardiovascular drugs in regulated markets and India. EPS is Rs 79.20. PE is 11.58x (remarkably cheap!), ROE 15.38 percent, D/E 0.08. Div 0.54 percent.
Glenmark Life Sciences: Glenmark Life Sciences earns from APIs and CDMO services for pharma companies. EPS is Rs 49.12. PE is 27.04x, ROE 16.94 percent, D/E 0.02.
Latest Results and Financial Data
On the Natco Pharma vs Glenmark Life Sciences results front: Natco Pharma has a market cap of Rs 16,427 Cr and PE of 11.58x. ROE is 15.38 percent. Natco and Glenmark Life Sciences are near-identical in market cap – separated by only Rs 119 Cr!
Glenmark Life Sciences has a market cap of Rs 16,308 Cr and PE of 27.04x. ROE is 16.94 percent. The two companies are essentially equal in size but Natco is much cheaper on PE (11.58x vs 27.04x).
Compare Natco Pharma and Glenmark Life Sciences Fundamentals on the Univest Screener
Stock Performance and Valuation
Investors tracking the Natco Pharma vs Glenmark Life Sciences comparison should verify current prices on NSE or BSE before trading. The Natco Pharma vs Glenmark Life Sciences stock data below reflects the latest available figures from Groww and public company filings.
Natco Pharma vs Glenmark Life Sciences at current valuations: Natco trades at Rs 16,427 Cr market cap, PE 11.58x (very cheap), ROE 15.38 percent. Glenmark Life Sciences trades at Rs 16,308 Cr market cap, PE 27.04x, ROE 16.94 percent. Near-identical market caps with very different PE ratios. Natco is a value proposition on PE; Glenmark Life Sciences has a slight edge on ROE.
Natco Pharma vs Glenmark Life Sciences: Quick Comparison Table
The comparison table below summarises the key metrics side by side.
| Parameter | Natco Pharma | Glenmark Life Sciences |
|---|---|---|
| Sector | Complex generic formulations: oncology + hepatitis + cardio (US exports) | API + CDMO services for global pharma (Glenmark subsidiary) |
| Market Cap | Rs 16,427 Cr | Rs 16,308 Cr (near-equal!) |
| P/E Ratio | 11.58x (very cheap!) | 27.04x |
| ROE | 15.38% | 16.94% |
| Debt to Equity | 0.08 | 0.02 |
| Model | Complex generics (own filings in US) | API manufacturer + CDMO services |
| Dividend Yield | 0.54% | 0.38% |
Conclusion
The Natco Pharma vs Glenmark Life Sciences comparison above covers reach, products, results and valuation. Natco Pharma vs Glenmark Life Sciences is a rare near-equal-size pharma comparison with very different business models. Natco is a complex generic formulations company with a very cheap PE – a potentially attractive valuation. Glenmark Life Sciences is an API and CDMO company growing with outsourcing demand. Natco vs Glenmark Life Sciences investors should track US generic drug price trends and CDMO order book growth respectively. Consult a SEBI-registered advisor for personalised guidance.
Download the Univest iOS App or Univest Android App to track Natco Pharma and Glenmark Life Sciences live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does Natco Pharma make?
Ans. Natco Pharma makes complex generic formulations – particularly cancer (oncology), hepatitis C (sofosbuvir, daclatasvir) and cardiovascular generic medicines. Natco licenses generic rights under voluntary licensing agreements from innovator companies for affordable medicines in developing markets.
What does Glenmark Life Sciences make?
Ans. Glenmark Life Sciences manufactures APIs (active pharmaceutical ingredients) – the chemical raw materials that go into finished medicines – for branded and generic pharma companies globally through CDMO contracts.
What is CDMO in pharma?
Ans. CDMO (Contract Development and Manufacturing Organization) provides pharmaceutical companies with chemistry R&D, process development, scale-up and manufacturing services on a contract basis. Glenmark Life Sciences provides these services through its API manufacturing facilities.
Why is Natco Pharma PE so cheap?
Ans. Natco Pharma’s PE of 11.58x is unusually low for a pharma company. This could reflect investor caution around US generic drug pricing pressure, paragraph IV challenges or concentration risks.
Are Natco Pharma and Glenmark Life Sciences in Nifty 50?
Ans. Neither is in Nifty 50. Both are tracked in smaller indices.
Which is larger, Natco or Glenmark Life Sciences?
Ans. Natco Pharma at Rs 16,427 Cr and Glenmark Life Sciences at Rs 16,308 Cr are virtually identical in size – one of the closest-matched pairs in this batch.
Is Glenmark Life Sciences part of Glenmark Pharmaceuticals?
Ans. Yes. Glenmark Life Sciences is a separately listed subsidiary of Glenmark Pharmaceuticals. The two are independently listed with different business profiles – Glenmark Pharmaceuticals sells finished branded medicines while Glenmark Life Sciences makes APIs.
